GRAIL, Inc. $GRAL Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP raised its position in shares of GRAIL, Inc. (NASDAQ:GRAL) by 88.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 408,650 shares of the company’s stock after purchasing an additional 191,857 shares during the quarter. Dimensional Fund Advisors LP’s holdings in GRAIL were worth $21,104,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Royal Bank of Canada lifted its holdings in shares of GRAIL by 17.7% during the first quarter. Royal Bank of Canada now owns 88,082 shares of the company’s stock worth $2,250,000 after purchasing an additional 13,264 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in GRAIL by 28.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock worth $76,000 after buying an additional 623 shares during the last quarter. NewEdge Advisors LLC lifted its stake in GRAIL by 390.3% during the 1st quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock valued at $45,000 after acquiring an additional 1,401 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in GRAIL by 37.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 92,465 shares of the company’s stock valued at $2,362,000 after acquiring an additional 25,177 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in shares of GRAIL by 115.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 79,544 shares of the company’s stock valued at $4,090,000 after acquiring an additional 42,675 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on GRAL shares. TD Cowen reiterated a “buy” rating on shares of GRAIL in a research note on Wednesday, July 15th. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research report on Friday, July 17th. Wolfe Research assumed coverage on shares of GRAIL in a report on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Mizuho increased their price target on GRAIL from $58.00 to $65.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. Finally, Wall Street Zen upgraded GRAIL from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $67.78.

Insider Buying and Selling

In related news, insider Andrew John Partridge sold 1,491 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total value of $91,070.28. Following the completion of the sale, the insider owned 163,738 shares of the company’s stock, valued at approximately $10,001,117.04. The trade was a 0.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.83% of the company’s stock.

GRAIL Stock Down 14.5%

Shares of GRAIL stock opened at $63.40 on Friday. The firm has a market cap of $2.72 billion, a PE ratio of -6.50 and a beta of 3.24. GRAIL, Inc. has a twelve month low of $29.95 and a twelve month high of $118.84. The business has a 50-day moving average price of $66.76 and a 200 day moving average price of $66.48.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.66) by $0.10. GRAIL had a negative return on equity of 16.05% and a negative net margin of 236.95%.The company had revenue of $44.69 million for the quarter, compared to the consensus estimate of $42.39 million. On average, sell-side analysts expect that GRAIL, Inc. will post -10.91 EPS for the current year.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.